Drug Trial Radar · NCT06949267
A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Jun 1, 2025
Primary completion
Sep 30, 2026
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Ruijin HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 29, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, randomized, controlled clinical trial to explore the efficacy and safety of iMSC in preventing the development of acute graft-versus-host disease of degree III-IV in patients after allogeneic hematopoietic stem cell transplantation.
Conditions
- Acute Graft-versus-Host Disease
Interventions
iMSCBiological
1× 10\^6/kg each time, twice a week
conventional aGVHD prophylaxisCombination product
Cyclosporine or tacrolimus(CNI)+Mycophenolate mofetil(MMF)± Short Course Methotrexate(MTX)+Anti-human T-lymphocyte Globulin(ATG)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative incidence of degree III-IV aGvHDTime frame: Within 100 days of first dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.